Clinical Trial Update: Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol G trial evaluating crizotinib for cancers with ROS1 genetic changes reports updated results and current status (Phase 2, active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Malignant Neoplasms

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-09-28